These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 25037281)

  • 1. Association of mastocytosis with inflammatory joint diseases: a series of 31 patients.
    Bader-Meunier B; Bulai Livideanu C; Larroche C; Durieu I; Artru L; Beucher A; Cormier G; Cornec D; Delarco M; Dubost JJ; Fontaine C; Gourin MP; Javier RM; de Jauréguiberry JP; Maisonneuve H; Toussirot E; Ugo V; Echaubard S; Mahlaoui N; Aouba A; Bodemer C; Briot K; Frenzel L; Lortholary O; Chandesris MO; Hermine O;
    Semin Arthritis Rheum; 2014 Dec; 44(3):362-5. PubMed ID: 25037281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologic treatment for rheumatic disease: real-world big data analysis from the Greek country-wide prescription database.
    Sfikakis PP; Bournia VK; Sidiropoulos P; Boumpas DT; Drosos AA; Kitas GD; Konstantonis G; Liossis SN; Manoussakis MN; Sakkas L; Tektonidou M; Tzioufas AG; Vlachoyiannopoulos PG; Kani C; Paterakis P; Litsa P; Vassilopoulos D
    Clin Exp Rheumatol; 2017; 35(4):579-585. PubMed ID: 28281458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
    Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
    Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease.
    Cepeda EJ; Williams FM; Ishimori ML; Weisman MH; Reveille JD
    Ann Rheum Dis; 2008 May; 67(5):710-2. PubMed ID: 18079191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of influenza-like illness into a cohort of patients affected by chronic inflammatory rheumatism and treated with biological agents.
    Bello SL; Serafino L; Bonali C; Terlizzi N; Fanizza C; Anecchino C; Lapaldula G
    Reumatismo; 2012 Dec; 64(5):299-306. PubMed ID: 23256105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative study of renal dysfunction in patients with inflammatory arthropathies: strong association with cardiovascular diseases and not with anti-rheumatic therapies, inflammatory markers or duration of arthritis.
    Haroon M; Adeeb F; Devlin J; O Gradaigh D; Walker F
    Int J Rheum Dis; 2011 Aug; 14(3):255-60. PubMed ID: 21816021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab treatment for spondyloarthritis. A nationwide series: data from the AIR registry of the French Society of Rheumatology.
    Wendling D; Dougados M; Berenbaum F; Brocq O; Schaeverbeke T; Mazieres B; Marcelli C; Leparc JM; Bertin P; Robin M; Sibilia J; Lafforgue P; Prati C; Combe B; Gottenberg JE;
    J Rheumatol; 2012 Dec; 39(12):2327-31. PubMed ID: 22896028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease-modifying anti-rheumatic drugs for refractory severe knee synovitis in patients with peripheral spondyloarthritis: efficacy and predictors of response.
    Sakellariou GT; Sayegh FE; Anastasilakis AD; Bisbinas I; Kapetanos GA
    Scand J Rheumatol; 2013; 42(5):369-72. PubMed ID: 23607529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insights into the pathology and treatment of spondyloarthritis: from the bench to the clinic.
    Davis JC; Mease PJ
    Semin Arthritis Rheum; 2008 Oct; 38(2):83-100. PubMed ID: 18166219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early tumor necrosis factor α antagonist therapy in everyday practice for inflammatory back pain suggesting axial spondyloarthritis: results from a prospective multicenter french cohort.
    Canouï-Poitrine F; Poulain C; Molto A; Le Thuaut A; Lafon C; Farrenq V; Ferkal S; Le Corvoisier P; Ghaleh B; Bastuji-Garin S; Fautrel B; Dougados M; Claudepierre P
    Arthritis Care Res (Hoboken); 2014 Sep; 66(9):1395-402. PubMed ID: 24664935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Indications and adverse events with the use of anti-TNFalpha agents in pediatric rheumatology: experience of a single center].
    de Oliveira SK; de Almeida RG; Fonseca AR; Rodrigues MC; Sztajnbok F; Diniz C
    Acta Reumatol Port; 2007; 32(2):139-50. PubMed ID: 17572652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors.
    Kapetanovic MC; Roseman C; Jönsson G; Truedsson L; Saxne T; Geborek P
    Arthritis Rheum; 2011 Dec; 63(12):3723-32. PubMed ID: 21834061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological therapies in the spondyloarthritides--the current state.
    Braun J; Sieper J
    Rheumatology (Oxford); 2004 Sep; 43(9):1072-84. PubMed ID: 15187239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baseline comorbidities in patients with rheumatoid arthritis who have been prescribed biological therapy: a case control study.
    Espiño-Lorenzo P; Manrique-Arija S; Ureña I; Jiménez-Núñez FG; López-Lasanta M; Romero-Barco CM; Belmonte-López MA; Irigoyen MV; Fernández-Nebro A
    Reumatol Clin; 2013; 9(1):18-23. PubMed ID: 22938792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ten-year drug survival of anti-TNF agents in the treatment of inflammatory arthritides.
    Biggioggero M; Favalli EG
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S38-41. PubMed ID: 25381973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors associated with withdrawal of the anti-TNFα biologics in the treatment of rheumatic diseases: data from the Hong Kong Biologics Registry.
    Mok CC; Chan KY; Lee KL; Tam LS; Lee KW;
    Int J Rheum Dis; 2014 Dec; 17 Suppl 3():1-8. PubMed ID: 24382315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease.
    Smith JR; Levinson RD; Holland GN; Jabs DA; Robinson MR; Whitcup SM; Rosenbaum JT
    Arthritis Rheum; 2001 Jun; 45(3):252-7. PubMed ID: 11409666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases.
    Wendling D; Paccou J; Berthelot JM; Flipo RM; Guillaume-Czitrom S; Prati C; Dernis E; Direz G; Ferrazzi V; Ristori JM;
    Semin Arthritis Rheum; 2011 Dec; 41(3):503-10. PubMed ID: 21862108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy.
    Tse SM; Burgos-Vargas R; Laxer RM
    Arthritis Rheum; 2005 Jul; 52(7):2103-8. PubMed ID: 15986366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors in a large cohort of patients with early undifferentiated inflammatory arthritis after application of a structured management protocol.
    Quinn MA; Green MJ; Marzo-Ortega H; Proudman S; Karim Z; Wakefield RJ; Conaghan PG; Emery P
    Arthritis Rheum; 2003 Nov; 48(11):3039-45. PubMed ID: 14613264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.